Literature DB >> 15257393

[Long-term changes in peripheral blood leukocyte and lymphocyte populations in ENT-carcinoma patients. A flow cytometric study in 346 ENT-carcinoma patients and 31 healthy controls].

J Ostwald1, S Dommerich, U Schulz, B Kramp.   

Abstract

BACKGROUND AND AIM: The aim of this investigation was the quantification of leukocyte/lymphocyte populations in the peripheral blood of ENT-carcinoma patients before and long after therapy. PROBANDS AND
METHOD: PBL T-lymphocytes and NK-cells were examined in 346 patients and 31 controls using flow cytometry. In 248 participants additional populations of leukocytes, monocytes, granulocytes, lymphocytes in toto, CD4+- and CD8+-lymphocytes, CD4+8+-lymphocytes, B-lymphocytes, activated T-lymphocytes, NK-cells and CD3+56+-T-lymphocytes were studied.
RESULTS: We demonstrated a long-term reduction in T-lymphocytes (CD4+-lymphocytes) in patients more than 10 years after receiving therapy, caused mainly, but not solely, by radio/chemotherapy. We also showed a long-term, significant increase in NK-cells after more than 10 years in patients following therapy without renewed carcinoma in comparison to controls, patients prior to therapy or patients with a recurrence of carcinoma.
CONCLUSIONS: Due to long-term deficits in CD4+-lymphocytes, and considering the possible protective effect of NK-cells in treated patients, an immune-supportive therapy is recommended.

Entities:  

Mesh:

Year:  2004        PMID: 15257393     DOI: 10.1007/s00106-003-0945-4

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  19 in total

1.  [Immunosuppression caused by head and neck surgery].

Authors:  F Heimlich; A Dietz; V Daniel; H Maier
Journal:  HNO       Date:  1999-10       Impact factor: 1.284

2.  [Cellular immune defect caused by postoperative irradiation in patients with squamous epithelial carcinomas of the upper aerodigestive tract].

Authors:  H Maier; V Daniel; F Heimlich; C Frank; G Opelz
Journal:  HNO       Date:  1995-06       Impact factor: 1.284

Review 3.  Late effects of radiation on the human immune system: an overview of immune response among the atomic-bomb survivors.

Authors:  M Akiyama
Journal:  Int J Radiat Biol       Date:  1995-11       Impact factor: 2.694

Review 4.  Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates.

Authors:  D R Vlock
Journal:  Hematol Oncol Clin North Am       Date:  1991-08       Impact factor: 3.722

5.  Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer.

Authors:  Thomas Bauernhofer; Iris Kuss; Brent Henderson; Andrew S Baum; Theresa L Whiteside
Journal:  Eur J Immunol       Date:  2003-01       Impact factor: 5.532

6.  Limiting dilution analysis of proliferating and cytotoxic lymphocytes in the peripheral blood and tumours of oral cancer patients.

Authors:  A Laad; J Kode; S Chavan; R Rao; A R Fakih; S Chiplunkar
Journal:  Eur J Cancer B Oral Oncol       Date:  1996-09

7.  Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer.

Authors:  S P Schantz; N G Ordonez
Journal:  Nat Immun Cell Growth Regul       Date:  1991

8.  Natural killer cell activity in patients with invasive cervical carcinoma: importance of a longitudinal evaluation in follow-up.

Authors:  G G Garzetti; A Ciavattini; M Muzzioli; G Goteri; B Mannello; C Romanini; N Fabris
Journal:  Gynecol Obstet Invest       Date:  1995       Impact factor: 2.031

9.  Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis.

Authors:  G T Wolf; S Schmaltz; J Hudson; H Robson; T Stackhouse; K A Peterson; J A Poore; K D McClatchey
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1987-11

10.  Autonomous production of granulocyte-colony stimulating factor in tumour xenografts associated with leukocytosis.

Authors:  Y Katoh; M Nakamura; Y Ohnishi; K Shimamura; Y Ueyama; N Tamaoki
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.